Cholinesterase inhibitor adjunctive therapy for cognitive impairment and depressive symptoms in older adults with depression;Uso de inhibidores de colinesterasa como tratamiento adjunto en pacientes ancianos con depresión y síntomas de depresión y problemas cognitivos

Annals of Pharmacotherapy

Volumn 46, Issue 4, 2012, Pages 599-605

  McDermott, Cara L ^a   Gray, Shelly L ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cholinesterase inhibitors; Cognition; Cognitive impairment; Depression; Donepezil; Galantamine

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CHOLINESTERASE INHIBITOR; CITALOPRAM; DONEPEZIL; DULOXETINE; ESCITALOPRAM; GALANTAMINE; SERTRALINE; VENLAFAXINE;

AGED; ATTENTION; COGNITION; COGNITIVE DEFECT; DEPRESSION; DEPTH PERCEPTION; DIZZINESS; DRUG EFFICACY; FATIGUE; GASTROINTESTINAL SYMPTOM; HAMILTON SCALE; HEADACHE; HEART DISEASE; HUMAN; HYPERSOMNIA; LANGUAGE; MANIA; MEMORY; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; SIDE EFFECT; SLEEP DISORDER; SWEATING; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTIDEPRESSIVE AGENTS; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; DEPRESSION; DRUG THERAPY, COMBINATION; GALANTAMINE; HUMANS; INDANS; PHENYLCARBAMATES; PIPERIDINES;

EID: 84859711747     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q445     Document Type: Review

References (23)

1. Steffens DC, Otey E, Alexopoulous GS, et al. Perspectives on depression, mild cognitive impairment, and cognitive decline. Arch Gen Psychiatry 2006;63:130-8.
2. Wilkins VM, Kiosses D, Ravdin LD. Late-life depression with comorbid cognitive impairment and disability: nonpharmacological interventions. Clin Interv Aging 2010;5:323-31.
3. Rosenberg PB, Mielke MM, Xue QL, Carlson MC. Depressive symptoms predict incident cognitive impairment in cognitive healthy older women. Am J Geriatr Psychiatry 2010;18:204-11.
4. Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D. Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry 2006;63:530-8.
5. Driscoll HC, Basinski J, Mulsant BH, et al. Late-onset major depression: clinical and treatment-response variability. Int J Geriatr Psychiatry 2005;20:661-7.
6. Baldwin R, Jeffries S, Jackson A, et al. Treatment response in late-onset depression: relationship to neuropsychological, neuroradiological and vascular risk factors. Psychol Med 2004;34:125-36.
7. Alexopoulos GS, Meyers BS, Young RC, et al. Executive dysfunction and long-term outcomes of geriatric depression. Arch Gen Psychiatry 2000;57:285-90.
8. Bassil N, Grossberg GT. Novel regimens and delivery systems in the pharmacological treatment of Alzheimer's disease. CNS Drugs 2009;23: 293-307.
9. Ago Y, Koda K, Takuma K, Matsuda T. Pharmacological aspects of the acetylcholinesterase inhibitor galantamine. J Pharmacol Sci 2011;116:6-17.
10. Alexopoulos GS, Kiosses DN, Heo M, Murphy CF, Shanmugham B, Gunning-Dixon F. Executive dysfunction and the course of geriatric depression. Biol Psychiatry 2005;58:204-10.
11. Waldemar G, Gauthier S, Jones R, et al. Effect of donepezil on emergence of apathy in mild to moderate Alzheimer's disease. Int J Geriatr Psychiatry 2011;26:150-7. DOI 10.1002/gps.2507.
12. Rodda J, Morgan S, Walker Z. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. Int Psychogeriatr 2009;21:813-24.
13. Dagyte G, Den Boer JA, Trentani A. The cholinergic system and depression. Behav Brain Res 2011;221:574-82.
14. Holtzheimer PE 3rd, Meeks TW, Kelley ME, et al. A double blind, placebo-controlled pilot study of galantamine augmentation of antidepressant treatment in older adults with major depression. Int J Geriatr Psychiatry 2008;23:625-31.
15. Elgamal S, MacQueen G. Galantamine as an adjunctive treatment in major depressive disorder. J Clin Psychopharmacol 2008;28:357-9.
16. Bogner HR, Bruce ML, Reynolds CF 3rd, et al. The effects of memory, attention, and executive dysfunction on outcomes of depression in a primary care intervention trial: the PROSPECT study. Int J Geriatr Psychiatry 2007;22:922-9.
17. Reynolds CF, Butters MA, Lopez O, et al. Maintenance treatment of depression in old age: a randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy. Arch Gen Psychiatry 2011;68:51-60.
18. Pelton GH, Harper OL, Tabert MH, et al. Randomized double-blind placebo-controlled donepezil augmentation in antidepressant-treated elderly patients with depression and cognitive impairment: a pilot study. Int J Geriatr Psychiatry 2008;23:670-6.
19. Raschetti R, Albanese E, Vanacore N, Maggini M. Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials. PLoS Med 2007;4:1818-28.
20. Doody RS, Ferris SH, Salloway S, et al. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Neurology 2009;72:1555-61.
21. Lu PH, Edland SD, Teng E, et al. Donepezil delays progression to AD in MCI subjects with depressive symptoms. Neurology 2009;72:2115-21.
22. Gildengers AG, Butters MA, Chisholm D, Reynolds CF, Mulsant BH. A 12-week open-label pilot study of donepezil for cognitive functioning and instrumental activities of daily living in late-life bipolar disorder. Int J Geriatr Psychiatry 2008;23:693-8.
23. Benazzi F. Mania associated with donepezil. J Psychiatry Neurosci 1999;24:468-9.